The U.S. Pharmacokinetics Services Market is still growing since pharmaceutical and biotech firms are increasingly depending on information about how their drugs behave quantitatively in order to determine their dosage, safety, and submission for approval. The pharmacokinetics services that include the absorption, distribution, metabolism, and excretion of drugs form the core of successful drug development.
As per SNS Insider, the U.S. Pharmacokinetics Services Market held value of approximately USD 0.44 Billion in 2025, which is expected to rise to approximately USD 0.97 Billion by 2035, recording a CAGR of approximately 8.21% during 2026-2035. The drivers for growth include the FDA's 'Model-Informed Drug Development' guidance, ICH E11(R1)'s pediatric extrapolation modeling strategy, and the remarkably high number of ongoing clinical studies within the country. It follows the growth pattern of the global Pharmacokinetics Services Market, having valued USD 1.38 Billion in 2025 and rising to USD 3.02 Billion by 2035 at a CAGR of 7.70% driven by the expanding biopharmaceutical pipeline and rising adoption of model-informed drug development across major markets.
To Get more information on Pharmacokinetics Services Market – Request Sample Report
Why the U.S. Leads Global Demand
The United States is the most commercially active pharmacokinetics services market, represented by companies like Charles River Laboratories, Covance (Labcorp Drug Development), ICON plc, PAREXEL, and Certara, whose business operations determine the commercial PK services map. FDA regulations and the high level of U.S. biopharmaceutical clinical trials generate the highest commercially focused PK services demand on the global scale.
North America generated nearly 37.1% of the total market revenue in 2025, of which 87.4% is contributed by the U.S. Such statistics are explained by the availability of highly qualified professionals working in clinical pharmacology, as well as developed bioanalytical technology, and the number of big pharmaceutical and CROs based in the region.
Segment Trends Shaping the U.S. Market
Small molecules account for approximately 68% of the global market share, owing to the presence of an established regulatory environment as well as libraries of historical PK datasets. Biologics and large molecules represent the fastest-growing type of drugs, since the evolution of the pipeline towards monoclonal antibodies, bispecific antibodies, ADCs, and gene therapies will require more advanced tools than those for small molecules.
Bioanalytical services accounted for 42% share among service types in 2025, whereas PK/PD modeling and simulation represents the fastest-growing segment due to acceptance by regulators of model-informed drug discovery in submissions. Preclinical studies by clinical phase account for 35% share in 2025, whereas Phase I is the fastest-growing phase owing to first-in-human design intensity as well as growth in oncology combination study volumes.
Companies Driving Innovation in the U.S. Market
Charles River Laboratories
Charles River’s range of pharmacokinetics services was enhanced in 2023 with the addition of novel bioanalytical technologies for the quantitation of small molecules as well as biologics. The reason behind this move is that there is an increasing need on the part of the clients for methods of large molecule quantitation such as ligand binding assays and immunoaffinity LC-MS/MS technologies.
Labcorp
In January 2024, Labcorp obtained FDA clearance for an AI-based PK modeling software, which predicts the behavior of drugs in the human body. With this software, clinical pharmacologists are able to determine the best dose regimen based on very limited PK data, with higher statistical certainty. This will help in lowering the sample size for first-in-human Phase I trials, thus saving time and money for pharmaceutical clients.
Certara L.P.
In 2024, Certara updated its Phoenix WinNonlin Population PK modeling software by adding more sophisticated AI-assisted modeling capabilities, covariate analysis automation, and generation of reports for submission to regulatory bodies. The update is aimed at clinical pharmacologists who need to shorten their modeling process while still achieving high standards of submission quality, thus meeting FDA needs for model-informed drug development.
Other established providers active in the U.S. include ICON plc, PAREXEL International, Eurofins Scientific, and Frontage Laboratories, each contributing to the country's expanding PK services infrastructure.
Market Dynamics
The growing U.S. biopharmaceutical pipeline is currently the major growth factor, with each new IND filing having a set PK service path running from preclinical ADME to clinical bioanalysis and modeling. The high cost of services and skill needs continue to be the significant challenges, especially hindering smaller biotech players due to limited budget at the early development stage.
The use of AI for PK predictions is the most evident near-term opportunity, with the FDA approval by Labcorp in 2024 providing a clear regulatory path for the industry, which the rest of players will likely adopt due to pharmaceutical customers’ requests.
The Future of the U.S. Pharmacokinetics Services Market
Growth in the U.S. market is assured up until 2035 due to the ongoing FDA focus on model-driven approaches for drug development, growing pipeline of biologics and gene therapies, and increased usage of AI-enabled modeling technologies. Suppliers that have made investments in the bioanalytical capacity for large molecules, AI-enabled modeling platforms, and biologics know-how are well-positioned for growth in the U.S. clinical development market environment.
